Ruxolitinib: a review of its use in patients with myelofibrosis.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing previously published clinical trial results without systematic review methodology.
PubMed 25601187 · doi:10.1007/s40265-015-0351-8
What was done
This narrative review summarizes clinical trial evidence evaluating ruxolitinib, an oral Janus kinase (JAK) 1 and 2 inhibitor, for the treatment of patients with intermediate-2 or high-risk myelofibrosis. The review synthesizes findings primarily from the phase III COMFORT-I and COMFORT-II trials, their extension phases, a trial in Japanese/Asian patients, and studies in patients with baseline low platelet counts.
What was found
The abstract provides no numerical data, effect sizes, or confidence intervals. It qualitatively reports that ruxolitinib achieved marked and durable reductions in splenomegaly and disease-related symptoms, alongside improvements in health-related quality of life and functioning. A survival advantage was reported despite crossover from control groups. Benefits occurred across subgroups, including patients lacking the JAK2V617F mutation and those with low baseline platelet counts. Dose-related anemia and thrombocytopenia were common adverse events, rarely led to discontinuation, and were managed by dosage adjustments or packed red blood cell transfusions.
Why it matters
This review highlights the clinical evidence supporting ruxolitinib as a targeted therapy capable of improving spleen size, constitutional symptoms, and overall survival across diverse myelofibrosis patient subsets.
Limits
The abstract contains no quantitative data or participant sample sizes. As a narrative review rather than a systematic review or primary study report, it does not include formal risk-of-bias assessments, study selection criteria, or meta-analytic pooling.
Cited by
- supports Ruxolitinib is used in the treatment of the bone marrow disorder myelofibrosis.